Introduction
retinal-vein thrombosis and thrombocytopenia of 128 000/ml. The suspected diagnosis of heparin-induced Heparin is at present the most widely used anticoagu-thrombocytopenia (HIT II ) was confirmed by the lant for haemodialysis to prevent clotting in the extra-heparin-induced platelet activation test (HIPA). The corporal circuit. Heparin-induced thrombocytopenia HIPA test was performed as described with a few (HIT ) type II is a serious complication rendering the modifications [6 ] . Further dialysis treatments were further administration of unfractioned heparin as well performed without anticoagulation at a blood flow as low-molecular-weight heparin impossible. Even rate of 250-300 ml/min for 3-h haemodialysis sessions available heparinoids such as danaparoid exhibit a without clotting events. The patient was on 100 mg significant cross-reactivity with HIT antibodies in acetylsalicylic acid daily and did well. In August 1998 5-10% of patients and is sometimes not suitable for overall Kt/V decreased below 1.0 because of declining anticoagulation in cases of heparin intolerance. residual renal function and haemodialysis duration was Hirudin is a direct thrombin inhibitor which forms increased to 4.5 h per session. This led to repeated non-covalent complexes with thrombin. In contrast to clotting of the dialyser or the extracorporeal circuit heparin it does not require endogenous cofactors. during the last treatment hour. Anticoagulation with Chronic administration of r-hirudin in haemodialysis r-hirudin (RefludanA, Fa. Hoechst-Marion Roussel, carries the risk of accumulation since unchanged hiru-Frankfurt, Germany) was started at a dose of din is exclusively cleared by the kidney [1]. It is not 0.06 mg/kg (5 mg) as a bolus at the beginning of each removed by haemodialysis. To avoid cumulation and dialysis-session. The anticoagulatory effect of r-hirudin bleeding complications in anuric patients dose reduc-was monitored by aPTT with a recommended range tion has been suggested (bolus of 0.02-0.17 mg/kg of 36-44 s. prior to each haemodialysis) followed by careful monAfter 16 dialysis sessions using r-hirudin the patient itoring with the activated partial thromboplastin time developed spontaneous haemorrhage into the left (aPTT ) [2] [3] [4] [5] .
quadriceps muscle following an episode of post-dialytic cramps. Haemoglobin level decreased from 9.4 g/dl to 8.1 g/dl. Two days later he suffered rectal bleeding,
Case
and haemoglobin level decreased further to 6.6 g/dl; PT (114%), fibrinogen (319 mg/dl ), and platelets A 49-year-old male patient developed renal failure (214 000/ml ) were within normal limits, aPTT was 44 s. presumably because of glomerulonephritis secondary r-Hirudin and acetylsalicylic acid were discontinued to acute endocarditis in June 1994. He was treated and 3 units of blood were transfused. Bleeding stopped with antibiotics and replacement of the aortic-valve by spontaneously. The ecarin clotting time ( ECT ) was a bioprosthesis. In March 1998 he became dialysis 289 s (normal range <50 s r-hirudin was further reduced to a dose of 0.018 mg/kg residual renal function serious bleeding occurred, although we used the recommended low dose of hirudin (1.5 mg) per session as bolus at the beginning of the treatment. With this reduced dosage of r-hirudin ECT and the aPTT was still in the therapeutic range. The bleeding risk would have been detected by the ECT, remained normal or slightly elevated and no clotting or bleeding tendency occurred for 3 months.
which was elevated more than five times above the upper normal value. A reduced dose of r-hirudin was administered as a bolus, and ECT as well as aPPT were monitored. With this approach no further bleed- Semin Thromb 1996; 22: 197-202 complications, drug monitoring by a sensitive test is 9. Griessbach U, Stü rzebecher J, Markwardt F. Assay of hirudin needed. Currently the aPTT is recommended for this in plasma using a chromogenic thrombin substrate assay. Thromb Res 1985; 37: 347-350 purpose by the manufacturers. In our patient without
